Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page : D5 {" j. k4 Q- d( P& s
( n5 |& y3 m3 \: p4 \' n, r5 L& |0 k3 ^+ E
Sub-category:* `7 W- }1 S) k+ u2 ?7 M
Molecular Targets
! O; q& _9 @( w, C* ?
5 u; ]& k, @+ V+ M& a1 W: V: _
Category:
. x6 D5 z/ c) Z( s! b7 D LTumor Biology ) K" X1 j3 q# |& v& j+ j% |
: {# O1 Z0 \3 E& N7 \5 u9 r
7 L! K1 c6 J+ l/ q! L- F" d* S. }: GMeeting:% H0 s. X4 X; P3 ?3 p
2011 ASCO Annual Meeting - r7 ?2 }* N$ U- S8 M
$ ^) x3 R( B0 E' U/ H6 G7 Z' ]# O; g5 E' p' k) P# J2 y: S
Session Type and Session Title:9 {4 H/ N1 ~8 h$ ] k! n, p
Poster Discussion Session, Tumor Biology ) V3 X, a! U: }" ~! O
& x1 i( O" E; o! ~
8 O2 F1 G1 O9 u& w0 s+ rAbstract No:
8 i* Y0 \1 f% D10517 a9 X5 \- [4 B0 T$ G
$ l& o- W9 D* k( H% E$ G
7 r+ m5 p! }/ R l4 N' H
Citation:$ o4 Y* p( t& \& n) N0 r
J Clin Oncol 29: 2011 (suppl; abstr 10517) 3 d) W n; @9 i
& Y( N$ t6 ~: u% G+ G& H; t9 {8 k& @
Author(s):
) P# V7 q/ q$ F; B) ?) E6 RJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
3 ]7 z, h o W3 ~% O
& P7 q* B& `! _% B$ P! J+ P% {- }3 ^8 ] r2 `4 g# Z9 Q* o) ^
% |$ M. d6 w- c6 w9 i, l9 v( ]Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
1 I# I+ \ ]7 b4 e
. j& G( h4 o" j/ G' |) W7 k4 `Abstract Disclosures
) a8 g3 x6 g9 ]; E0 Y4 J7 r5 B
& u9 }6 o3 Z5 ~- V/ L" i% TAbstract:
l Z) I5 l1 g2 F$ O, @ d3 w! ^
- d: W* r! A k
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
" ?- e2 C T0 _/ T, b5 P/ t: y a( l" D- w- l
2 G4 U+ X" ~4 ?. \/ T$ m- [# ^9 U |
肺癌历经手术-复发-脑转移，如今母亲
讲述者：一只阿狸整理者：pear
熟悉我家的朋友都知道，我母亲虽然是IB期肺癌，但是很
安禹堂产品真实反馈
患友使用安禹堂皮肤抑菌液、手足平、甲沟炎凝胶真实反馈
中日友好医院科研转化产品安
求助求助：妈妈的基因检测结果，EGFR
请版主帮忙@一下大神们，帮忙出一下注意。
帖子更新到2025年3月7日，首次手术样本，送
“振”守脑膜-脑膜转移的诊疗现状及
整理者：志愿者
脑膜转移，常被广大病友称为“终极转移”——癌细胞犹如乘坐“特快列
胸心港湾·共筑希望——EGFR突变NSCL
在抗击肺癌的道路上，每一个患者和家庭需要的不仅仅是在医院的诊疗，更是来自全方位的
7 N+ ?% e: @7 N/ w5 u! }* b
显身卡
